Primary immune deficiencies (PIDs) are a group of rare disorders of the immune system, resulting in increased susceptibility to infections, autoimmunity and malignancies. The most severe forms of PIDs are fatal, unless immune reconstitution is achieved by hematopoietic cell transplantation (HCT), enzyme replacement or gene therapy. Because of the many disease- and treatment-related variables that may affect outcome after HCT, both careful collection of data in Registries and multicenter collaboration are needed to facilitate analysis of outcome and development of prospective clinical trials. In 2009, the Primary Immune Deficiency Treatment Consortium (PIDTC) was established in North America with the goal of building a North American collaboration to carry-out retrospective, cross-sectional and prospective studies that would define risk factors, long term outcomes and late effects in children with Severe Combined Immunodeficiency (SCID), Wiskott-Aldrich Syndrome (WAS) and Chronic Granulomatous Disease (CGD) who receive HCT or other forms of definitive treatment. In April 2011 the first annual PIDCT Scientific Workshop was held in San Francisco followed by workshops in Boston (2012), Houston (2013), Seattle (2014), Montreal (2015) and Los Angeles (2016). These workshops and Education Days provide a unique and critical forum to assemble experienced and young investigators from all major centers in North America involved in the treatment of these disorders, as well as biostatisticians and Patient Advocacy Groups and have been responsible for initiating the development of national and international collaborations. The proposed 7th PIDTC Scientific Workshop and Education Day in Bethesda, MD (PIDTC2017) will focus on new timely topics to further advance the development of clinical trials aimed at improving treatment of PIDs, immunobiology of PIDs, the microbiome, gene therapy, and collaborations with Patient Advocacy Groups. The specific objectives of the workshops are: 1) To disseminate information on survival, clinical status, and immune function in patients with severe PIDs who have received HCT or other forms of treatment 2) To initiate data collection and analysis in other forms of severe PIDs that can be treated by HCT 3) To analyze relevance of biological markers that predict successful immune reconstitution following HCT 4) To discuss the results of novel approaches to HCT for PID that may minimize transplant-related toxicity while allowing robust and durable engraftment and immune reconstitution 5) To develop optimal treatment protocols for newborns with SCID. 6) To prompt development of clinical trials in the field of HCT for PIDs 7) To promote education of young investigators with a specific interest in treatment of PIDs 8) To increase synergy among Patient Advocacy Groups actively involved in PID awareness campaigns
The Primary Immune Deficiency Treatment Consortium (PIDTC) was established in North America with the goal of building multicenter collaboration to improve outcome in primary immune deficiency (PID) patients who receive hematopoietic cell transplantation (HCT) or other forms of treatment. The first six PIDTC Annual Scientific Workshops beginning in 2011 focused on critical topics for patients with Severe Combined Immunodeficiency (SCID), Wiskott-Aldrich Syndrome (WAS) and Chronic Granulomatous Disease (CGD). The proposed PIDTC Scientific Workshop and Education Day in Bethesda in May 2017 will assemble experienced and young investigators from all major centers in North America in addition to international experts from the UK involved in the study and treatment of PIDs and patient advocacy groups focused on families and patients with PID. The theme will be PIDs associated with autoinflammation and autoimmunity as well as the role of the microbiome in PID.
Showing the most recent 10 out of 30 publications
